Lamotrigine(BW430C LTG) - 半岛电竞官方网址

Molecular Weight (MW)	256.09
Formula	C9H7Cl2N5
CAS No.	84057-84-1
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 10 mg/mL (39.0 mM)
Water: <1 mg/mL
Ethanol: 3 mg/mL (11.7 mM)
Solubility (In vivo)	0.5% methylcellulose: 30 mg/mL
Synonyms	BW-430C; Lamotrigine, Lamictal, BW 430C; BW430C; Crisomet, Lamictin, Lamitor

Molecular Weight (MW)

256.09

Formula

C9H7Cl2N5

CAS No.

84057-84-1

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 10 mg/mL (39.0 mM)

Water: <1 mg/mL

Ethanol: 3 mg/mL (11.7 mM)

Solubility (In vivo)

0.5% methylcellulose: 30 mg/mL

Synonyms

BW-430C; Lamotrigine, Lamictal, BW 430C; BW430C; Crisomet, Lamictin, Lamitor

In Vitro	In vitro activity: Lamotrigine stabilises presynaptic neuronal membranes by blockade of voltage-dependent sodium channels, thus preventing the release of excitatory neurotransmitters, particularly glutamate and aspartate. In rat cerebral cortex tissue incubated with veratrine 10 mg/L, lamotrigine is twice as potent in inhibiting the release of glutamate and aspartate (ED 50 = 5.38 mg/L for each) than the release of GABA (ED50 = 11.2 mg/L), and is much less potent in inhibiting acetylcholine release (ED50 = 25.6 mg/L) when cortical slices is exposed to veratrine 75 mg/L. Basal glutamate release is unaffected. Lamotrigine inhibits high-frequency sustained repetitive firing of sodium-dependent action potentials, indicating a direct effect on voltage-activated sodium channels. Lamotrigine does not induce PCP-like central nervous system (CNS) effects, does not act by direct inhibition at the NMDA receptor, and would be expected to be devoid of the undesirable effects associated with NMDA blockade.
In Vivo	In mice and rats, lamotrigine prevents MES- and pentetrazol-induced hindlimb extension, suggesting an antiepileptic profile in animals. These effects peak 1 hour after lamotrigine administration and persist for more than 24 hours. Lamotrigine is active in the electrically evoked EEG after-discharge test, which is thought to indicate activity against both simple and complex partial seizures. After-discharge duration is reduced dose-dependently by lamotrigine in rats at intravenous doses>5 mg/kg.
Animal model	Dog/Rat
Formulation & Dosage	Dissolved in 0.25% methylcellulose solution; 4.5 (dogs) and 11.7 (rats) mg /kg; i.v. injection
References	Drugs. 1993 Jul;46(1):152-76; Epilepsia. 1986 Sep-Oct;27(5):483-9.

In Vitro

In vitro activity: Lamotrigine stabilises presynaptic neuronal membranes by blockade of voltage-dependent sodium channels, thus preventing the release of excitatory neurotransmitters, particularly glutamate and aspartate. In rat cerebral cortex tissue incubated with veratrine 10 mg/L, lamotrigine is twice as potent in inhibiting the release of glutamate and aspartate (ED 50 = 5.38 mg/L for each) than the release of GABA (ED50 = 11.2 mg/L), and is much less potent in inhibiting acetylcholine release (ED50 = 25.6 mg/L) when cortical slices is exposed to veratrine 75 mg/L. Basal glutamate release is unaffected. Lamotrigine inhibits high-frequency sustained repetitive firing of sodium-dependent action potentials, indicating a direct effect on voltage-activated sodium channels. Lamotrigine does not induce PCP-like central nervous system (CNS) effects, does not act by direct inhibition at the NMDA receptor, and would be expected to be devoid of the undesirable effects associated with NMDA blockade.

In Vivo

In mice and rats, lamotrigine prevents MES- and pentetrazol-induced hindlimb extension, suggesting an antiepileptic profile in animals. These effects peak 1 hour after lamotrigine administration and persist for more than 24 hours. Lamotrigine is active in the electrically evoked EEG after-discharge test, which is thought to indicate activity against both simple and complex partial seizures. After-discharge duration is reduced dose-dependently by lamotrigine in rats at intravenous doses>5 mg/kg.

Animal model

Dog/Rat

Formulation & Dosage

Dissolved in 0.25% methylcellulose solution; 4.5 (dogs) and 11.7 (rats) mg /kg; i.v. injection

References

Drugs. 1993 Jul;46(1):152-76; Epilepsia. 1986 Sep-Oct;27(5):483-9.

CAS NO:	84057-84-1
规格:	≥98%

包装	价格(元)
2g	电议
5g	电议
10g	电议
25g	电议